Biogen (NASDAQ:BIIB) said that three of its board members will no longer stand for reelection at the company’s upcoming annual meeting, which it plans to adjourn until June 26.
The biotech company said Alexander Denner, William Jones and Richard Mulligan will not seek re-election to the board, with Susan Langer now standing for election.
A former head of corporate strategy for Biogen, Langer is president of Souffle Therapeutics.
Biogen also confirmed that Caroline Dorsa will succeed Stelios Papadopoulos as board chair following the annual meeting.
The company said that in order to give shareholders more time to consider the changes, it will adjourn the annual meeting scheduled for June 14 to reconvene on June 26.
More on Biogen:
Biogen stock doesn’t see big boost from FDA panel endorsement of Leqembi
FDA panel recommends full approval for Biogen, Eisai Alzheimer’s drug
Alzheimer’s disease market expected to reach $14B globally in 2030